Related to Cylene Looks to Horizon to Identify Genetic Basis of Response to Oral Anticancer Drug

• Novartis Shells Out $210M for Two of Incyte’s Hematology-Oncology Candidates
  
• Minerva Grants Clarient Exclusive Rights to Develop MUC1* Biomarker for Cancer Diagnostics
  
• Forma Pockets $25.5M to Advance Cancer Drug Discovery Activities
  
• Bayer Schering Pharma Receives Chinese Approval for MS Drug and Signs Anticancer Deal with Micromet
  
• Pfizer and Crown Team Up to Develop Treatments for Asian Cancers
  
• Researchers Provide Systems-Level Dissection of Regulatory Perturbations in Cancer
  
• Ludwig Institute to Evaluate Pro-Pharmaceuticals’ Candidate for Its Ability to Enhance Antitumor T Cells
  
• Horizon Negotiates Licenses to Gene Engineering Technology from University of Washington
  
• Teva Buys OncoGenex' Late-Stage Anticancer Agent with $110M in Payments
  
• Scientists Use New Mouse Model to Visualize Metastasis Formation in Real Time
  
• Aura to Use CRT's Cancer-Targeting Peptides for Delivery
  
• Scientists Discover that Circulating Tumor Cells Can Return to Their Original Site
  
• Researchers Identify Protein that Inhibits Tumor-Targeting Immune Cells When Activated
  
• Dicerna and Kyowa Hakko Kirrin Ally on Cancer Drug R&D
  
• Oncomed to Exploit Fluidigm’s Microfluidic Devices in Cancer Stem Cell Research
  
• Predictive Biosciences Picks Up CLIA-Certified OncoDiagnostic Laboratory
  
• Ferrer InCode to Market BioTheranostics’ Cancer Classification Assay in Four Countries
  
• VentiRx Pockets $25M to Fund Clinical Development of TLR8 Candidates
  
• Formatech to Fill and Finish One Lot of ViroMed’s Preclinical Cancer Vaccine at No Charge
  
• Sage and Pfizer Team Up on Cancer Research